Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bumetanide for sensory processing disorders in children with ASD, ADHD, and/or epilepsy
NL-OMON45411Phase 2Completed
- Sponsor
- University Medical Center Utrecht
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in Autism Spectrum Disorder (ASD), attention deficit hyperactivity disorder (ADHD) and epilepsy comparing Bumetanide plus usual care with Placebo plus usual care (2 arms). Primary endpoint: Aberrant Behavior Checklist-Irritability subscale. Started Jun 2017; status: completed.
02
Drugs
bumetanide
03
Conditions
Autism Spectrum Disorder (ASD)attention deficit hyperactivity disorder (ADHD)epilepsy
Beyond the preview
Go deeper on NL-OMON45411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45411.